Disease block
C51-C58 – Bösartige Neubildungen der weiblichen Genitalorgane
- Chapter II: Neubildungen
26Decisions
36Patient groups
Added benefit by patient group
- Major1
- Considerable7
- Minor1
- Non-quantifiable1
- Not proven26
Diseases in this disease block
- C51 Bösartige Neubildung der Vulva 5 decisions
- C52 Bösartige Neubildung der Vagina 5 decisions
- C53 Bösartige Neubildung der Cervix uteri 9 decisions
- C54 Bösartige Neubildung des Corpus uteri 14 decisions
- C55 Bösartige Neubildung des Uterus, Teil nicht näher bezeichnet 5 decisions
- C56 Bösartige Neubildung des Ovars 13 decisions
- C57 Bösartige Neubildung sonstiger und nicht näher bezeichneter weiblicher Genitalorgane 13 decisions
- C58 Bösartige Neubildung der Plazenta 5 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-07-16ElahereMirvetuximab SoravtansinConsiderable
- 2026-02-19TivdakTisotumab VedotinNot proven: 3 of 3 patient groups
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-08-07JemperliDostarlimabNot proven
- 2025-05-15KeytrudaPembrolizumabNot proven: 2 of 2 patient groups
- 2025-05-15KeytrudaPembrolizumabNon-quantifiable
- 2025-02-20LynparzaOlaparibConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20ImfinziDurvalumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-02-20ImfinziDurvalumabNot proven
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-06-20JemperliDostarlimabMajor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-06-06RubracaRucaparibNot proven
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-10-19LibtayoCemiplimabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2023-09-21RubracaRucaparibNot proven
- 2023-09-21LynparzaOlaparibNot proven
- 2023-04-20LynparzaOlaparibConsiderable
- 2023-02-02KeytrudaPembrolizumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2023-01-19KeytrudaPembrolizumabNot proven
- 2022-07-07LenvimaLenvatinibConsiderable
- 2021-12-02JemperliDostarlimabNot proven
- 2021-07-15ZejulaNiraparibNot proven
- 2021-05-20ZejulaNiraparibNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2020-04-02VitrakviLarotrectinibNot proven
- 2018-12-06LynparzaOlaparibMinor
Data status: 2026-10-29